Public Profile

Cipla USA Inc.

Cipla USA Inc., a subsidiary of the renowned global pharmaceutical company Cipla Limited, is headquartered in the United States and operates extensively across North America. Founded in 1935, Cipla has established itself as a leader in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of a diverse range of high-quality generic and branded medications. Cipla USA is particularly noted for its commitment to providing affordable healthcare solutions, specialising in areas such as respiratory, oncology, and anti-infective therapies. The company’s innovative approach to drug formulation and delivery sets it apart in a competitive market. With a strong emphasis on research and development, Cipla USA has achieved significant milestones, including numerous FDA approvals, solidifying its position as a trusted provider of essential medicines.

DitchCarbon Score

How does Cipla USA Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

27

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Cipla USA Inc.'s score of 27 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Cipla USA Inc.'s reported carbon emissions

Cipla USA Inc. currently does not have available carbon emissions data for the most recent year, nor are there specific reduction targets or initiatives outlined in their climate commitments. Without concrete figures or defined goals, it is challenging to assess their current impact on carbon emissions or their strategic approach to climate change. In the broader context of the pharmaceutical industry, companies are increasingly focusing on sustainability and reducing their carbon footprints, but specific commitments from Cipla USA Inc. remain unspecified.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Cipla USA Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Cipla USA Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Cipla USA Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Lupin Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Eli Lilly and Company

GB
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sagent Pharmaceuticals, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Lannett Company, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Teva Pharmaceuticals

IL
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

ADVANZ PHARMA Corp. Limited

GB
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers